Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OPNT Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Opiant Pharmaceuticals Stock (NASDAQ:OPNT) 30 days 90 days 365 days Advanced Chart Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get Opiant Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$20.03▼$21.1052-Week Range N/AVolume562,700 shsAverage Volume77,920 shsMarket Capitalization$108.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOpiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.Read More… Receive OPNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address OPNT Stock News HeadlinesMovers From YesterdayOctober 10, 2024 | benzinga.comCNFinance Hldgs (NYSE:CNF) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comCackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. December 22, 2024 | DTI (Ad)Hikma Pharmaceuticals PLC ADR (HKMPY)April 18, 2024 | investing.comIonis PharmaceuticalsJanuary 31, 2024 | forbes.comUPDATE 2-US FDA approves Opiant's spray for reversing opioid-related overdosesMay 24, 2023 | msn.comREFILE-US FDA approves Opiant's overdose reversal sprayMay 23, 2023 | msn.comIndivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science PortfolioMarch 3, 2023 | msn.comSee More Headlines OPNT Stock Analysis - Frequently Asked Questions How were Opiant Pharmaceuticals' earnings last quarter? Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) posted its quarterly earnings data on Thursday, November, 11th. The technology company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.15 by $0.41. The technology company earned $16.34 million during the quarter, compared to analyst estimates of $12.45 million. Opiant Pharmaceuticals had a negative net margin of 147.90% and a negative trailing twelve-month return on equity of 97.03%. What other stocks do shareholders of Opiant Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Opiant Pharmaceuticals investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and AcelRx Pharmaceuticals (ACRX). Company Calendar Last Earnings11/11/2021Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OPNT CUSIPN/A CIK1108924 Webwww.opiant.com Phone(310) 598-5410Fax917-322-2105Employees37Year Founded2009Profitability EPS (Most Recent Fiscal Year)($6.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.01 million Net Margins-147.90% Pretax Margin-147.84% Return on Equity-97.03% Return on Assets-59.66% Debt Debt-to-Equity Ratio0.60 Current Ratio5.48 Quick Ratio5.48 Sales & Book Value Annual Sales$47.78 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow24.75 Book Value$9.92 per share Price / BookN/AMiscellaneous Outstanding Shares5,270,000Free Float3,865,000Market Cap$108.83 million OptionableNot Optionable Beta0.84 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:OPNT) was last updated on 12/22/2024 by MarketBeat.com Staff From Our Partners⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opiant Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opiant Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.